-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Given Average Rating of "Moderate Buy" by Analysts
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Given Average Rating of "Moderate Buy" by Analysts
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) has been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.69.
A number of equities analysts have commented on DNA shares. Bank of America lowered Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research note on Wednesday, May 18th. BTIG Research raised their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, August 16th. Raymond James raised their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a research note on Tuesday, August 16th. Finally, Jefferies Financial Group lowered their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a research note on Thursday, June 16th.
Get Ginkgo Bioworks alerts:Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lincoln National Corp bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $26,000. Atria Wealth Solutions Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $30,000. Cetera Investment Advisers bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $33,000. First Horizon Advisors Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $38,000. Finally, Endurance Wealth Management Inc. increased its position in Ginkgo Bioworks by 100.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company's stock valued at $40,000 after buying an additional 5,000 shares in the last quarter. 53.37% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Stock Performance
NYSE:DNA opened at $2.99 on Wednesday. The stock has a market cap of $5.34 billion, a P/E ratio of -1.53 and a beta of 1.84. The stock has a 50 day simple moving average of $2.98 and a 200 day simple moving average of $3.10. The company has a current ratio of 11.84, a quick ratio of 11.78 and a debt-to-equity ratio of 0.03. Ginkgo Bioworks has a 1-year low of $2.09 and a 1-year high of $15.86.Ginkgo Bioworks Company Profile
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Featured Stories
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) has been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.69.
據MarketBeat報道，銀杏生物工程控股公司(紐約證券交易所代碼：DNA-GET評級)已被目前報道該公司的八家經紀公司一致給予“適度買入”的建議。一位股票研究分析師對該股的評級為賣出，一位分析師給出了持有評級，五位分析師給出了該公司的買入評級。在過去一年發佈該股報告的分析師中，12個月目標價的平均水平為8.69美元。
A number of equities analysts have commented on DNA shares. Bank of America lowered Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research note on Wednesday, May 18th. BTIG Research raised their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, August 16th. Raymond James raised their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a research note on Tuesday, August 16th. Finally, Jefferies Financial Group lowered their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a research note on Thursday, June 16th.
許多股票分析師對DNA股票發表了評論。美國銀行將Ginkgo Bioworks的評級從中性下調至表現不佳，併為該股設定了3.00美元的目標價。在5月18日星期三的一份研究報告中。BTIG Research在8月16日週二的一份研究報告中將銀杏生物工場的目標價從5.00美元上調至6.00美元，並給予該股“買入”評級。雷蒙德·詹姆斯在8月16日星期二的一份研究報告中將銀杏生物科技公司的目標價從11.50美元上調至14.50美元，並給出了“跑贏大盤”的評級。最後，傑富瑞金融集團在6月16日星期四的一份研究報告中將銀杏生物工程的目標價從11.50美元下調至4.35美元。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lincoln National Corp bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $26,000. Atria Wealth Solutions Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $30,000. Cetera Investment Advisers bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $33,000. First Horizon Advisors Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $38,000. Finally, Endurance Wealth Management Inc. increased its position in Ginkgo Bioworks by 100.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company's stock valued at $40,000 after buying an additional 5,000 shares in the last quarter. 53.37% of the stock is owned by institutional investors and hedge funds.
一些對衝基金和其他機構投資者最近改變了他們在該業務中的頭寸。林肯國家公司在第二季度購買了銀杏生物工程公司的新股份，價值約2.6萬美元。Atria Wealth Solutions Inc.在第二季度以約3萬美元的價格購買了銀杏生物科技公司的新股份。其他投資顧問公司在第二季度購買了銀杏生物工程公司的新股份，價值約3.3萬美元。第一地平線顧問公司(First Horizon Advisors Inc.)在第二季度以約3.8萬美元的價格購買了銀杏生物科技公司的新股份。最後，耐力財富管理公司在第一季度將其在銀杏生物工程公司的頭寸增加了100.0%。耐力財富管理公司現在持有10,000股該公司股票，價值40,000美元，在上個季度又購買了5,000股。53.37%的股票由機構投資者和對衝基金持有。
Ginkgo Bioworks Stock Performance
銀杏生物工場股票表現
Ginkgo Bioworks Company Profile
銀杏生物工程公司簡介
(Get Rating)
(獲取評級)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
銀杏生物工程控股公司及其子公司開發細胞編程平臺。它的平臺用於對細胞進行編程，以實現產品的生物生產，如新型療法、食品配料和從石油中提取的化學品。該公司服務於各種終端市場，包括特種化學品、農業、食品、消費品和藥品。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免費獲取StockNews.com關於銀杏生物工程(DNA)的研究報告
- 這三份報告將告訴我們許多關於當前經濟的情況。
- 下面的五個是不是打得太高了？
- 這就是現在對標準普爾500指數的預期
- 關於甲骨文的FQ1報告，你需要知道的兩件事
- 波動市場的三隻價值股
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《銀杏生物工場日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對銀杏生物工程和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧